StockData

Innospec vs Ingevity

IOSP and NGVT side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IOSP and NGVT compare

Innospec and Ingevity are about the same size, with market caps of $1.9B and $2.0B.

Innospec grew revenue faster over the last twelve months (2.9% versus −1.4% for Ingevity).

Innospec pays a dividend yielding 3.5%; Ingevity does not pay one.

Innospec scores higher on the StockData Score (13 against 6 for Ingevity), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIOSPNGVT
Size and price
Market cap$1.9B$2.0B
Share price$78.01$59.28
Change, 1 year5.3%20.1%
Change, 5 years−6.2%−20.2%
Beta (5Y)1.100.76
Employees2,4501,500
StockData Score
Total score13 (better)6
Valuation score3 (better)0
Growth score12 (better)
Performance score13 (better)
Health score6 (better)1
Dividend score2 (better)0
Valuation
P/E–40.3×
P/S1.0× (better)1.8×
P/B1.4× (better)43.5×
EV/EBITDA9.9× (better)22.7×
P/FCF–13.2×
FCF yield–7.6%
Fair value$92.08$33.70
Margin of safety15.3% (better)−75.9%
Growth
Revenue growth (TTM)2.9% (better)−1.4%
Revenue growth, 5Y average8.3% (better)−0.81%
EPS growth, 5Y average32.1%–
Profitability
Gross margin27.5%41.1% (better)
Operating margin7.0%–
Net margin–4.7%
FCF margin–13.4%
Return on equity–64.4%
Return on invested capital10.4%–
Financial health
Debt / equity0.0025.59 (better)
Net debt / EBITDA–7.97
Current ratio2.78 (better)1.61
Altman Z-score4.85 (better)2.19
Piotroski F-score–6
Dividends and buybacks
Dividend yield3.5%–
Years of dividend growth12–
Dividend growth, 5Y average10.5%–
Buyback yield1.3%7.0% (better)
Shareholder yield4.8%7.0% (better)
Ownership
Held by institutions101%102%
Held by insiders1.6%1.4%
Insider net buying, 12 months−$874K (better)−$1.8M
Short interest, % of float1.9%3.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.